Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03694522




Registration number
NCT03694522
Ethics application status
Date submitted
14/09/2018
Date registered
3/10/2018
Date last updated
28/02/2024

Titles & IDs
Public title
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Scientific title
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Secondary ID [1] 0 0
2017-003507-22
Secondary ID [2] 0 0
FPA144-004 Phase 2
Universal Trial Number (UTN)
Trial acronym
FIGHT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastric Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Bemarituzumab
Treatment: Drugs - Placebo
Treatment: Drugs - Modified FOLFOX6

Experimental: Bemarituzumab + mFOLFOX6 - Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.

Placebo comparator: Placebo + mFOLFOX6 - Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.


Treatment: Other: Bemarituzumab
Administered by intravenous infusion over approximately 30 minutes

Treatment: Drugs: Placebo
Administered by intravenous infusion over approximately 30 minutes

Treatment: Drugs: Modified FOLFOX6
mFOLFOX6 regimen consists of the following:

* Oxaliplatin 85 mg/m² IV infusion over 120 minutes
* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable
* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Tumor assessments were performed every 8 weeks until 12 months and then every 12 weeks thereafter until disease progression or additional anticancer therapy was initiated; the median duration of follow-up time was 10.9 months.
Secondary outcome [3] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timepoint [3] 0 0
From first dose of study drug to 28 days after last dose of study drug. Actual median (min, max) duration of treatment emergent period was 29 (4.1, 157) weeks in the bemarituzumab + mFOLFOX6 group and 28 (4.3, 133) weeks in the placebo + mFOLFOX6 group.

Eligibility
Key inclusion criteria
Key

* Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
* Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1
* Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay
* Candidate for mFOLFOX6 chemotherapy

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Untreated or symptomatic central nervous system (CNS) metastases
* Clinically significant cardiac disease,
* Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
* Active infection requiring systemic treatment
* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection
* Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway
* Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
* Known positivity for human epidermal growth factor receptor 2 (HER2)
* Women who are pregnant or breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/09/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/05/2022
Sample size
Target
Accrual to date
Final
155
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Chris O'brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
The Townsville Hospital - Douglas
Recruitment hospital [3] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Douglas
Recruitment postcode(s) [3] 0 0
- Wahroonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Utah
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
Belgium
State/province [18] 0 0
Brugge
Country [19] 0 0
Belgium
State/province [19] 0 0
Libramont
Country [20] 0 0
Belgium
State/province [20] 0 0
Liege
Country [21] 0 0
Belgium
State/province [21] 0 0
Yvoir
Country [22] 0 0
China
State/province [22] 0 0
Anhui
Country [23] 0 0
China
State/province [23] 0 0
Hubei
Country [24] 0 0
China
State/province [24] 0 0
Jiangsu
Country [25] 0 0
China
State/province [25] 0 0
Beijing
Country [26] 0 0
China
State/province [26] 0 0
Changchun
Country [27] 0 0
China
State/province [27] 0 0
Changsha
Country [28] 0 0
China
State/province [28] 0 0
Chongqing
Country [29] 0 0
China
State/province [29] 0 0
Fuzhou
Country [30] 0 0
China
State/province [30] 0 0
Hangzhou
Country [31] 0 0
China
State/province [31] 0 0
Harbin
Country [32] 0 0
China
State/province [32] 0 0
Nantong
Country [33] 0 0
China
State/province [33] 0 0
Shanghai
Country [34] 0 0
China
State/province [34] 0 0
Shantou
Country [35] 0 0
China
State/province [35] 0 0
Shenyang
Country [36] 0 0
China
State/province [36] 0 0
Shijiazhuang
Country [37] 0 0
China
State/province [37] 0 0
Suzhou
Country [38] 0 0
China
State/province [38] 0 0
Tianjin
Country [39] 0 0
China
State/province [39] 0 0
Zhengzhou
Country [40] 0 0
France
State/province [40] 0 0
Besançon
Country [41] 0 0
France
State/province [41] 0 0
Brest
Country [42] 0 0
France
State/province [42] 0 0
Montbéliard
Country [43] 0 0
France
State/province [43] 0 0
Nancy
Country [44] 0 0
France
State/province [44] 0 0
Saint-Étienne
Country [45] 0 0
France
State/province [45] 0 0
Strasbourg
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Germany
State/province [47] 0 0
Braunschweig
Country [48] 0 0
Germany
State/province [48] 0 0
Frankfurt am Main
Country [49] 0 0
Germany
State/province [49] 0 0
Ludwigsburg
Country [50] 0 0
Germany
State/province [50] 0 0
Mannheim
Country [51] 0 0
Germany
State/province [51] 0 0
Mutlangen
Country [52] 0 0
Germany
State/province [52] 0 0
Oberpfalz
Country [53] 0 0
Hungary
State/province [53] 0 0
Budapest
Country [54] 0 0
Hungary
State/province [54] 0 0
Miskolc
Country [55] 0 0
Hungary
State/province [55] 0 0
Nyíregyháza
Country [56] 0 0
Hungary
State/province [56] 0 0
Pecs
Country [57] 0 0
Hungary
State/province [57] 0 0
Szolnok
Country [58] 0 0
Italy
State/province [58] 0 0
Ancona
Country [59] 0 0
Italy
State/province [59] 0 0
Avellino
Country [60] 0 0
Italy
State/province [60] 0 0
Aviano
Country [61] 0 0
Italy
State/province [61] 0 0
Brescia
Country [62] 0 0
Italy
State/province [62] 0 0
Candiolo
Country [63] 0 0
Italy
State/province [63] 0 0
Cremona
Country [64] 0 0
Italy
State/province [64] 0 0
Firenze
Country [65] 0 0
Italy
State/province [65] 0 0
Genova
Country [66] 0 0
Italy
State/province [66] 0 0
Legnago
Country [67] 0 0
Italy
State/province [67] 0 0
Meldola
Country [68] 0 0
Italy
State/province [68] 0 0
Milan
Country [69] 0 0
Italy
State/province [69] 0 0
Napoli
Country [70] 0 0
Italy
State/province [70] 0 0
Pavia
Country [71] 0 0
Italy
State/province [71] 0 0
Pisa
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
San Giovanni Rotondo
Country [74] 0 0
Italy
State/province [74] 0 0
Sondrio
Country [75] 0 0
Italy
State/province [75] 0 0
Torino
Country [76] 0 0
Italy
State/province [76] 0 0
Udine
Country [77] 0 0
Japan
State/province [77] 0 0
Chiba
Country [78] 0 0
Japan
State/province [78] 0 0
Kagawa
Country [79] 0 0
Japan
State/province [79] 0 0
Bunkyo-Ku
Country [80] 0 0
Japan
State/province [80] 0 0
Hiroshima
Country [81] 0 0
Japan
State/province [81] 0 0
Kawasaki
Country [82] 0 0
Japan
State/province [82] 0 0
Kitakyushu
Country [83] 0 0
Japan
State/province [83] 0 0
Koto-Ku
Country [84] 0 0
Japan
State/province [84] 0 0
Niigata
Country [85] 0 0
Japan
State/province [85] 0 0
Nishinomiya
Country [86] 0 0
Japan
State/province [86] 0 0
Osaka
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Gangnam
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Gyeonggi-do
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Gyeonggi
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Jeollabuk-do
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Namdong-gu
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
North Gyeongsang
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Busan
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Daejeon
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Seoul
Country [96] 0 0
Poland
State/province [96] 0 0
Bielsko-Biala
Country [97] 0 0
Poland
State/province [97] 0 0
Brzozów
Country [98] 0 0
Poland
State/province [98] 0 0
Lublin
Country [99] 0 0
Poland
State/province [99] 0 0
Olsztyn
Country [100] 0 0
Poland
State/province [100] 0 0
Otwock
Country [101] 0 0
Poland
State/province [101] 0 0
Rzeszów
Country [102] 0 0
Poland
State/province [102] 0 0
Warszawa
Country [103] 0 0
Portugal
State/province [103] 0 0
Aveiro
Country [104] 0 0
Portugal
State/province [104] 0 0
Braga
Country [105] 0 0
Portugal
State/province [105] 0 0
Guimarães
Country [106] 0 0
Portugal
State/province [106] 0 0
Porto
Country [107] 0 0
Portugal
State/province [107] 0 0
Santa Maria Da Feira
Country [108] 0 0
Portugal
State/province [108] 0 0
Senhora Da Hora
Country [109] 0 0
Romania
State/province [109] 0 0
Bucharest
Country [110] 0 0
Romania
State/province [110] 0 0
Cluj Napoca
Country [111] 0 0
Romania
State/province [111] 0 0
Cluj-Napoca
Country [112] 0 0
Romania
State/province [112] 0 0
Constanta
Country [113] 0 0
Romania
State/province [113] 0 0
Craiova
Country [114] 0 0
Romania
State/province [114] 0 0
Timisoara
Country [115] 0 0
Spain
State/province [115] 0 0
A Coruña
Country [116] 0 0
Spain
State/province [116] 0 0
Alcorcon
Country [117] 0 0
Spain
State/province [117] 0 0
Barcelona
Country [118] 0 0
Spain
State/province [118] 0 0
Girona
Country [119] 0 0
Spain
State/province [119] 0 0
Lleida
Country [120] 0 0
Spain
State/province [120] 0 0
Madrid
Country [121] 0 0
Spain
State/province [121] 0 0
Majadahonda
Country [122] 0 0
Spain
State/province [122] 0 0
Pamplona
Country [123] 0 0
Spain
State/province [123] 0 0
Sabadell
Country [124] 0 0
Spain
State/province [124] 0 0
Servilla
Country [125] 0 0
Spain
State/province [125] 0 0
Terrassa
Country [126] 0 0
Taiwan
State/province [126] 0 0
Taichung
Country [127] 0 0
Thailand
State/province [127] 0 0
Bankok
Country [128] 0 0
Thailand
State/province [128] 0 0
Chiang Rai
Country [129] 0 0
Thailand
State/province [129] 0 0
Hat Yai
Country [130] 0 0
Thailand
State/province [130] 0 0
Khon Kaen
Country [131] 0 0
Thailand
State/province [131] 0 0
Lampang
Country [132] 0 0
Turkey
State/province [132] 0 0
Adana
Country [133] 0 0
Turkey
State/province [133] 0 0
Ankara
Country [134] 0 0
Turkey
State/province [134] 0 0
Atakum
Country [135] 0 0
Turkey
State/province [135] 0 0
Aydin
Country [136] 0 0
Turkey
State/province [136] 0 0
Bursa
Country [137] 0 0
Turkey
State/province [137] 0 0
Gaziantep
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Izmir
Country [140] 0 0
Turkey
State/province [140] 0 0
Kocaeli
Country [141] 0 0
Turkey
State/province [141] 0 0
Malatya
Country [142] 0 0
Turkey
State/province [142] 0 0
Van
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Dundee

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Five Prime Therapeutics, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Zai Lab (Shanghai) Co., Ltd.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
Trial website
https://clinicaltrials.gov/study/NCT03694522
Trial related presentations / publications
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14.
Xiang H, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, Collins H. Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. Cancer Chemother Pharmacol. 2020 Nov;86(5):595-606. doi: 10.1007/s00280-020-04139-4. Epub 2020 Sep 23.
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03694522